logo
Twitter
Discord
Email
logo
Ascendis Pharma A/S

Ascendis Pharma A/S

NASDAQ•ASND
CEO: Mr. Jan Moller Mikkelsen
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-01-28
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Contact Information
Tuborg Boulevard 12, Hellerup, 2900, Denmark
45-70-22-22-44
ascendispharma.com
Market Cap
$12.58B
P/E (TTM)
-46.4
38.2
Dividend Yield
--
52W High
$229.94
52W Low
$118.03
52W Range
78%
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$249.73M+269.40%
4-Quarter Trend

EPS

-$1.17-40.83%
4-Quarter Trend

FCF

$2.45M-103.71%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Strong Revenue Growth Driven by Licensing Total revenue reached 363.6M EUR, up 96.9M EUR, primarily due to the 100.0M USD upfront payment from the Novo Nordisk license agreement.
YORVIPATH FDA Approval and Launch YORVIPATH received FDA approval and launched commercially in the US for adult hypoparathyroidism, contributing 28.7M EUR in revenue.
Operating Loss Significantly Reduced Operating loss improved by 176.8M EUR to (278.8M EUR), benefiting from increased revenue and lower research and development costs.
TransCon CNP Achondroplasia Data Positive Pivotal ApproaCH trial showed TransCon CNP achieved superior annualized growth velocity versus placebo in children with achondroplasia.

Risk Factors

Negative Equity and Future Financing Need Total equity remains negative at (105.7M EUR); future viability depends on obtaining additional capital on acceptable terms to fund operations.
Reliance on Single-Source Suppliers Loss or failure of single-source suppliers for parent drugs and components could materially and adversely affect business and supply chain.
Clinical Development Delays and Failure Clinical trials are lengthy and expensive with uncertain outcomes; delays or failure to obtain regulatory approval would substantially harm business.
Geopolitical Conflicts Disrupt Operations Conflicts like Russia/Ukraine and Israel/Hamas could adversely impact clinical trials, supply chain operations, regulatory timelines, and commercial activities.

Outlook

SKYTROFA Adult GHD Expansion sBLA submitted to FDA for SKYTROFA in adult GHD; PDUFA goal date is July 27, 2025, expanding market opportunity for TransCon hGH.
TransCon CNP Regulatory Submissions Planned NDA submission for TransCon CNP in pediatric achondroplasia planned for Q1 2025 (FDA), followed by MAA submission in Q3 2025 (EMA).
Novo Nordisk Collaboration Potential Exclusive worldwide license granted to Novo Nordisk for TransCon platform in metabolic and cardiovascular diseases, including 285M USD milestones.
Adequate Cash Runway Maintained Cash and cash equivalents totaled 559.5M EUR; expected to fund operations for at least the next twelve months based on current plan.

Peer Comparison

Revenue (TTM)

Baxter International Inc.BAX
$11.02B
-6.3%
BioMarin Pharmaceutical Inc.BMRN
$3.09B
+12.4%
Royalty Pharma plcRPRX
$2.35B
+3.7%

Gross Margin (Latest Quarter)

Royalty Pharma plcRPRX
100.0%
+0.0pp
Ionis Pharmaceuticals, Inc.IONS
98.5%
-0.7pp
Exelixis, Inc.EXEL
96.9%
+0.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RPRX$17.17B22.311.6%46.3%
MRNA$16.34B-5.2-31.4%6.0%
ROIV$16.09B-42.1-8.0%2.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
10.4%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 11, 2026
|
EPS:$0.05
|
Revenue:$285.52M
Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 12, 2025|
    Revenue: $393.38M+36.3%
    |
    EPS: $-7.06+23.6%
    Miss

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 7, 2024|
    Revenue: $288.50M+421.2%
    |
    EPS: $-9.25+17.8%
    Miss

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Feb 16, 2023|
    Revenue: $53.80M+557.9%
    |
    EPS: $-10.93-48.6%
    Miss

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 2, 2022|
    Revenue: $9.20M+11.9%
    |
    EPS: $-8.28+15.5%
    Beat

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Mar 10, 2021|
    Revenue: $7.93M-48.0%
    |
    EPS: $-9.44-76.5%
    Miss